These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 20483717)

  • 1. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.
    Kish SJ; Lerch J; Furukawa Y; Tong J; McCluskey T; Wilkins D; Houle S; Meyer J; Mundo E; Wilson AA; Rusjan PM; Saint-Cyr JA; Guttman M; Collins DL; Shapiro C; Warsh JJ; Boileau I
    Brain; 2010 Jun; 133(Pt 6):1779-97. PubMed ID: 20483717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.
    Erritzoe D; Frokjaer VG; Holst KK; Christoffersen M; Johansen SS; Svarer C; Madsen J; Rasmussen PM; Ramsøy T; Jernigan TL; Knudsen GM
    Arch Gen Psychiatry; 2011 Jun; 68(6):562-76. PubMed ID: 21646575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
    Thomasius R; Petersen K; Buchert R; Andresen B; Zapletalova P; Wartberg L; Nebeling B; Schmoldt A
    Psychopharmacology (Berl); 2003 Apr; 167(1):85-96. PubMed ID: 12632248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907.
    Urban NB; Girgis RR; Talbot PS; Kegeles LS; Xu X; Frankle WG; Hart CL; Slifstein M; Abi-Dargham A; Laruelle M
    Neuropsychopharmacology; 2012 May; 37(6):1465-73. PubMed ID: 22353758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.
    McCann UD; Szabo Z; Vranesic M; Palermo M; Mathews WB; Ravert HT; Dannals RF; Ricaurte GA
    Psychopharmacology (Berl); 2008 Oct; 200(3):439-50. PubMed ID: 18661256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain serotonin transporter binding in former users of MDMA ('ecstasy').
    Selvaraj S; Hoshi R; Bhagwagar Z; Murthy NV; Hinz R; Cowen P; Curran HV; Grasby P
    Br J Psychiatry; 2009 Apr; 194(4):355-9. PubMed ID: 19336788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.
    Buchert R; Thomasius R; Wilke F; Petersen K; Nebeling B; Obrocki J; Schulze O; Schmidt U; Clausen M
    Am J Psychiatry; 2004 Jul; 161(7):1181-9. PubMed ID: 15229049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecstasy-induced reduction of the availability of the brain serotonin transporter as revealed by [11C](+)McN5652-PET and the multi-linear reference tissue model: loss of transporters or artifact of tracer kinetic modelling?
    Buchert R; Thiele F; Thomasius R; Wilke F; Petersen K; Brenner W; Mester J; Spies L; Clausen M
    J Psychopharmacol; 2007 Aug; 21(6):628-34. PubMed ID: 17092972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.
    Di Iorio CR; Watkins TJ; Dietrich MS; Cao A; Blackford JU; Rogers B; Ansari MS; Baldwin RM; Li R; Kessler RM; Salomon RM; Benningfield M; Cowan RL
    Arch Gen Psychiatry; 2012 Apr; 69(4):399-409. PubMed ID: 22147810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.
    Vegting Y; Reneman L; Booij J
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3473-501. PubMed ID: 27568200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.
    McCann UD; Szabo Z; Seckin E; Rosenblatt P; Mathews WB; Ravert HT; Dannals RF; Ricaurte GA
    Neuropsychopharmacology; 2005 Sep; 30(9):1741-50. PubMed ID: 15841106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.
    Buchert R; Thomasius R; Petersen K; Wilke F; Obrocki J; Nebeling B; Wartberg L; Zapletalova P; Clausen M
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):188-99. PubMed ID: 16133393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET.
    Buchert R; Thomasius R; Nebeling B; Petersen K; Obrocki J; Jenicke L; Wilke F; Wartberg L; Zapletalova P; Clausen M
    J Nucl Med; 2003 Mar; 44(3):375-84. PubMed ID: 12621003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are ecstasy induced serotonergic alterations overestimated for the majority of users?
    Szigeti B; Winstock AR; Erritzoe D; Maier LJ
    J Psychopharmacol; 2018 Jul; 32(7):741-748. PubMed ID: 29733742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study.
    Gamma A; Buck A; Berthold T; Vollenweider FX
    J Clin Psychopharmacol; 2001 Feb; 21(1):66-71. PubMed ID: 11199950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy use.
    Laursen HR; Henningsson S; Macoveanu J; Jernigan TL; Siebner HR; Holst KK; Skimminge A; Knudsen GM; Ramsoy TZ; Erritzoe D
    J Psychopharmacol; 2016 Dec; 30(12):1296-1304. PubMed ID: 27599522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET.
    Buchert R; Obrocki J; Thomasius R; Väterlein O; Petersen K; Jenicke L; Bohuslavizki KH; Clausen M
    Nucl Med Commun; 2001 Aug; 22(8):889-97. PubMed ID: 11473208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroimaging research in human MDMA users: a review.
    Cowan RL
    Psychopharmacology (Berl); 2007 Jan; 189(4):539-56. PubMed ID: 16847678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.
    Reneman L; de Win MM; van den Brink W; Booij J; den Heeten GJ
    J Psychopharmacol; 2006 Mar; 20(2):164-75. PubMed ID: 16510475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.